Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06982417

InsightRP2 Registry

InsightRP2 is a secure online patient registry specific to RP2-associated retinitis pigmentosa (RP). It is our goal to further the scientific understanding of this rare disease and to support research in to a gene therapy for RP2-associated RP.

We collect medical, genetic and imaging data from people affected by RP2-associated RP and will coduct a natural history study as well as image analysis studies.

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

University Medicine Göttingen

Göttingen, Lower Saxony, 37073, Germany

Location status: Recruiting

Location contact

Bernd Wollnik, MD, Prof.

CONTACT

[email protected]

+49 (0)551 / 39-67589

Bernd Wollnik, MD, Prof.

PRINCIPAL_INVESTIGATOR

Nina Bögershausen, MD

CONTACT

[email protected]

+49 (0)551 / 39-69016

About this study

There is currently no specific patient registry for RP2-associated retinitis pigmentosa. Due to the rarity of the disease, only a few patients with this disease are seen at various care sites, making clinical care and diagnosis very challenging. In addition, there are numerous knowledge gaps regarding the course of the disease, the disease mechanisms and therapeutic approaches, which poses additional challenges for patient care. Understanding and future treatment of RP2-associated RP is crucial due to its early onset and rapid progression. There is an urgent need for targeted research to develop effective therapies.

At the Institute of Human Genetics Göttingen, we have set ourselves the goal of investigating the disease mechanisms of RP2-associated RP and contributing to the long-term development of a therapy for this rare disease.

For this purpose, we have set up a patient registry specifically for RP2-associated RP. The registry is fully online, using a secure REDCap-based database hosted at the University Medical Center Göttingen. The medical data collected will enable us to conduct studies on the natural history, mutation distribution and possible genotype-phenotype correlations of this disease. In addition, the collection of medical image data will enable evaluation for the purpose of improving diagnostic processes and supporting therapeutic studies. Last but not least, we aim to form a patient collective who can be offered participation in possible therapy studies at a later date.

We will collect retrospective data, however patient's might be recontacted at a later timepoint, which is why we have designated the time perspective as "other" in the description of the study design.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A molecular genetic diagnosis involving a heterozygous or hemizygous variant in RP2 and a written informed consent to participate are required for access to the registry questionnaire. Patients of all ages meeting the above criteria will be allowed to participate. As documentation will be in English and German, those who can navigate these pages will be included.

Exclusion criteria

  • Patients with evidence of non-RP2 molecular genetic diagnoses will be excluded. Collection of data and further analysis will not be possible without the consent of the patient or legal guardian. Patients who cannot navigate registry documentation in English or German will be excluded.

Treatment and study plan

Primary outcomes

  1. Genotype-phenotype correlation age of onset

    Time frame: 1 year

    Influence of variant type on age of onset

  2. Phenotype-genotype correlation progression

    Time frame: 20 years

    Influence of variant type on disease progression

Study contacts

Contact information is provided by the study sponsor or research team.

Bernd Wollnik, MD, Prof.

CONTACT

[email protected]

+49 (0)551 / 39-67589

Nina Bögershausen, MD

CONTACT

[email protected]

+49 (0)551 / 39-69016

Sponsors and collaborators

Lead sponsor

University of Göttingen

Other

Registry information

Official study title

InsightRP2: a Global Patient Registry for RP2-associated Retinitis Pigmentosa

Important dates

Study start
2025
Primary completion
2045
Study completion
2045
First posted
May 21, 2025
Registry last updated
May 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.